CSPC Innovation Pharmaceutical Co., Ltd. / Fundamentals
Income statement
- Net revenue
€249.13M - Cost of goods sold
€151.55M - Gross profit
€97.58M - SG&A expenses
€21.25M - R&D expenses
€126.56M - EBITDA
-€52.36M - D&A
-€47.21K - EBIT
-€53.15M - Interest expenses
€1.37M - EBT
-€53.85M - Tax expenses
€9.01M - Net income
-€10.41M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€9.86M - Changes in working capital
€0.00 - Operating cash flow
-€9.58M - Capex
€46.66M - Other investing cash flow
€12.15M - Net investing cash flow
-€87.55M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
€58.25M - Net financing cash flow
€58.25M - Foreign exchange effects
€3.22M - Net change in cash
-€79.98M - Cash at end of period
€98.60M - Free cash flow
€37.08M
Balance sheet
- Cash and cash equivalents
€98.70M - Cash and short-term investments
€155.05M - Total receivables
€77.24M - Inventory
€52.47M - Other current assets
€63.79M - Total current assets
€348.55M - Property, plant & equipment
€325.59M - Goodwill
€0.00 - Intangible assets
€26.87M - Long-term investments
€34.76M - Other non-current assets
€8.08M - Total non-current assets
€397.60M - Total assets
€746.15M - Accounts payable
€65.47M - Short-term debt
€14.84M - Other current liabilities
€129.43M - Total current liabilities
€211.23M - Long-term debt
€0.00 - Deferred tax liabilities
€244.98K - Other non-current liabilities
€0.00 - Total non-current liabilities
€15.47M - Total liabilities
€226.70M - Common stock
€169.99M - Retained earnings
€155.58M - Other equity
€44.14M - Total equity
€519.46M - Total liabilities and shareholders' equity
€746.15M
Company information
- Market capitalization
€8.64B - Employees
2.5K - Enterprise Value
€83.61B
Company ratios
- Gross margin
-
39.2% Worse than peer group: 48.2% - EBITDA margin
-
-21.0% Much worse than peer group: 17.0% - EBIT margin
-
-21.3% Much worse than peer group: 12.5% - EBT margin
-
-21.6% Much worse than peer group: 12.7% - Net margin
-
-4.2% Worse than peer group: 10.5% - ROE
-
-2.0% Worse than peer group: 10.0% - ROA
-
-1.4% Worse than peer group: 6.6% - Asset turnover
-
33.4% Much worse than peer group: 61.6% - FCF margin
-
-22.6% Much worse than peer group: 0.6% - FCF yield
-0.7% - Efficiency ratio
121.0% - Net sales per employee
-
€100.17K - Net income per employee
-
-€4.19K